GandhiRT, BedimoR, HoyJF, et al.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel. JAMA, 2023; 329(1):63–84; doi: 10.1001/jama.2022.22246
2.
SaxPE, ThompsonMA, SaagMS, IAS-USA Treatment Guidelines Panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel. JAMA, 2024; 331(12):1060–1061; doi: 10.1001/jama.2024.2985
3.
NguyenNM, KavanaghR, GozarM, et al.Implementation of a pharmacist-led, long-acting, injectable cabotegravir/rilpivirine program for HIV-1 at health system-based clinics in New York metropolitan area. AIDS Patient Care STDS, 2024; 38(3):115–122; doi: 10.1089/apc.2023.0250
4.
OrkinC, SchapiroJM, PernoCF, et al.Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: Clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis, 2023; 77(10):1423–1431; doi: 10.1093/cid/ciad370
5.
MasichAM, GomesD, HigginsonRT, et al.HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program. AIDS, 2023; 37(10):1641–1642; doi: 10.1097/QAD.0000000000003590
6.
KityoC, MambuleIK, MusaaziJ, et al.CARES trial team. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): Week 48 results from a randomized, multicentre, open-label, non-inferiority trial. Lancet Infect Dis, 2024; S1473-3099(24):289; doi: 10.1016/S1473-3099(24)00289-5
